definiens: means the average [ * * * ] of the three approved bra nded PD- 1 monoclonal antibodies ( or the average [ * * * ] of all approved branded PD- 1 monoclonal antibodies listed on the [ * * * ] if there are less than three such bran ded PD- 1 monoclonal antibodies ) that have the highest market share by volume in the ZAI Lab Territory ( ex cluding ( a ) the Licensed Product(s ) from such approved branded PD-1 monoclonal antibodies and ( b ) molecules that are not Covered by a Valid Claim of a Patent Covering a composition of matter, formu lations or method of treatment or use of such molecule(s ) in the Zai Lab Territory ), as updated o n the first Business Day of each Calendar Quarter during the term of this Agreement . As of the Effect i ve Date, the approved PD- 1 monoclonal antibodies are pembrolizumab, nivolumab, sintilimab and toripa limab